BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Detail)

Stockholders' Equity - Additional Information (Detail)								3 Months Ended		6 Months Ended
Stockholders' Equity - Additional Information (Detail)	Jun. 15, 2018 $ / shares shares	May 14, 2018 $ / shares shares	May 10, 2018 shares	May 09, 2018 shares	Mar. 01, 2018 shares	Jan. 26, 2018 $ / shares shares	Jan. 25, 2018 $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($) $ / shares shares	Mar. 06, 2018 USD ($) $ / shares	Dec. 31, 2017 shares
Stockholders Equity [Line Items]
Reverse stock split ratio			0.2
Description of reverse stock split										At BIOLASE’s annual meeting of stockholders on May 9, 2018 (the “Annual Meeting”), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of BIOLASE common stock, at a ratio ranging from one-for-five (1:5) to one-for-fifteen (1:15), with the final ratio to be determined by the BIOLASE board of directors (the “Board”). Immediately after the Annual Meeting, the Board approved a one-for-five (1:5) reverse stock split of the outstanding shares of BIOLASE common stock (the “Reverse Stock Split”). On May 10, 2018, the Company filed an amendment (the “Amendment”) to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of 11:59 p.m. on May 10, 2018. The Amendment also reduced the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares.
Common stock, shares authorized			40,000,000	200,000,000				40,000,000		40,000,000			40,000,000
Compensation expense related to stock options \| $								$ 600,000	$ 800,000	$ 1,300,000	$ 1,100,000
Net impact of stock-based compensation expense to earnings per basic share \| $ / shares								$ (0.03)	$ (0.06)	$ (0.06)	$ (0.08)
Net impact of stock-based compensation expense to earnings per diluted share \| $ / shares								$ (0.03)	$ (0.06)	$ (0.06)	$ (0.08)
Total unrecognized compensation expense \| $								$ 3,600,000		$ 3,600,000
Unrecognized share based compensation expense to be recognized over weighted-average period										2 years
Reversal of share based compensation expense \| $										$ 100,000	$ 500,000
Outstanding stock options, RSUs and warrants excluded from diluted loss per share								5,100,000	5,400,000	5,100,000	5,400,000
Western Alliance Warrant
Stockholders Equity [Line Items]
Initial exercise price of warrants \| $ / shares												$ 2.35
Stock Options
Stockholders Equity [Line Items]
Number of shares subject to awards granted										402,000
Stock Options \| Employees
Stockholders Equity [Line Items]
Stock options granted							360,000
Awards valued per share \| $ / shares							$ 2.11
Options expiration period							10 years
Options vesting description										The options vest ratably over the 36-month period, commencing on February 25, 2018.
Share-based Compensation Arrangement by Share-based Payment Award, Monthly Ratable Award Vesting Period							36 months
Share Based Compensation Arrangement By Share Based Payment Award, Vesting Commencement Date							Feb. 25, 2018
Restricted Stock Units (RSUs)
Stockholders Equity [Line Items]
Granted										2,456,000
Restricted Stock Units (RSUs) \| Employees
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares		$ 1.45
Options vesting description										These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and were fully vested on the grant date.
Granted		10,127
Restricted Stock Units (RSUs) \| Board Members
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares		$ 1.45
Options vesting description										398,275 shares to certain Board members of the Company. These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and fully vest on the first anniversary of the grant date
Granted		398,275
Restricted Stock Units (RSUs) \| New Board Members
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares	$ 1.25
Options vesting description										These awards were valued at $1.25 per share, the closing price of BIOLASE common stock on the grant date, and vest fully on May 9, 2019.
Granted	155,000
Award vesting date	May 09, 2019
2002 Stock Incentive Plan
Stockholders Equity [Line Items]
Common stock authorized for issuance								3,100,000		3,100,000
Common stock issued pursuant to options exercised										900,000
Options and restricted stock units outstanding								1,900,000		1,900,000
2002 Stock Incentive Plan \| Restricted Stock Units (RSUs) \| President And Chief Executive Officer
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares						$ 2.00
Granted						40,000
2018 Long-Term Incentive Plan
Stockholders Equity [Line Items]
Common stock authorized for issuance				2,120,547				2,035,287		2,035,287
Options and restricted stock units outstanding								1,600,000		1,600,000
Number of shares subject to awards granted					85,260
Options available for future grants								400,000		400,000
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Board Members, Employees and Consultants
Stockholders Equity [Line Items]
Awards valued per share \| $ / shares		$ 1.45
Options vesting description										These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and vest 40% on December 31, 2018 and 60% on December 31, 2019, subject to continued service through the applicable vesting date.
Granted		1,193,850
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Board Members, Employees and Consultants \| Vest on December 31, 2018
Stockholders Equity [Line Items]
Vesting percentage		40.00%
Award vesting date		Dec. 31, 2018
2018 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Board Members, Employees and Consultants \| Vest on December 31, 2019
Stockholders Equity [Line Items]
Vesting percentage		60.00%
Award vesting date		Dec. 31, 2019
Minimum [Member]
Stockholders Equity [Line Items]
Reverse stock split ratio				0.2
Maximum
Stockholders Equity [Line Items]
Reverse stock split ratio				0.067
Maximum \| Western Alliance Warrant
Stockholders Equity [Line Items]
Warrants issued to purchase shares of common stock equal value \| $												$ 120,000